Concepedia

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger, K. Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert E. Blum, Jane Robertson, Juliane M. Jürgensmeier,

Journal of Clinical Oncology · 2007 · 302 citations · 27 references

DOI

Abstract

Once-daily oral AZD2171 at doses of 45 mg or less was generally well tolerated and was associated with encouraging antitumor activity in patients with a broad range of advanced solid tumors.

References

27

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Aram V. Chobanian · JAMA · 2003 · 25.4K citations

, , +19

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

Takayuki Asahara, Toyoaki Murohara, Alison Sullivan et al. · Science · 1997 · 8.7K citations

, , +13

Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

Donald R. Senger, Stephen J. Galli, Ann M. Dvořàk et al. · Science · 1983 · 4K citations

, , +18